5-硝基-1-苯并呋喃-2-甲醛 | 23145-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 5-硝基-1-苯并呋喃-2-甲醛
• 英文名称: 5-nitro-benzofuran-2-carbaldehyde
• 英文别名: 2-formyl-5-nitro-1-benzofuran；5-Nitro-1-benzofuran-2-carbaldehyde
• CAS: 23145-18-8
• 化学式: C₉H₅NO₄
• mdl: MFCD06255199
• 分子量: 191.143
• InChiKey: NJHFCKIZFVVFTC-UHFFFAOYSA-N

物化性质

• 熔点：
  161-163°
• 沸点：
  352.8±22.0 °C(Predicted)
• 密度：
  1.471±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  5-硝基-1-苯并呋喃-2-甲醛 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 以63.5%的产率得到(5-硝基-1-苯并呋喃-2-基)甲醇
  参考文献：
  名称：

  A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs

  摘要：

  Reports on the comprehensive factors for design considerations of hypoxia-activated prodrugs (HAPs) are rare. We introduced a new model system composed of a series of highly water-soluble HAPs, providing a platform to comprehensively understand the interaction between HAPs and hypoxic biosystems. Specifically, four kinds of new HAPs were designed and synthesized, containing the same biologically active moiety but masked by different bioreductive groups. Our results demonstrated that the activity of the prodrugs was strongly dependent on not only the molecular structure but also the hypoxic tumor microenvironment. We found the presence of a direct linear relationship between cytotoxicity of the HAPs and the reduction potential of whole molecule/oxygen concentration/reductase expression. Moreover, limited blood vasculature in hypoxic regions was also a critical barrier for effective activation of the HAPs. This study offers a comprehensive insight into understanding the design factors required for HAPs.

  DOI：

  10.1021/acs.molpharmaceut.0c00232
• 作为产物：
  描述：

  苯并[b]呋喃-2-甲醛 在 硫酸 、 硝酸 作用下， 生成 5-硝基-1-苯并呋喃-2-甲醛
  参考文献：
  名称：

  Kakimoto et al., Nippon Kagaku Zasshi, 1953, vol. 74, p. 636

  摘要：

  DOI：

文献信息

• Benzoxazepinones and their use as squalene synthase inhibitors
  申请人：——

  公开号：US20030078251A1

  公开（公告）日：2003-04-24

  There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

  披露了一种由公式[I]表示的化合物： 1 其中R 1 是可选地取代的1-羧乙基，可选地取代的烷基亚磺酰基，可选地取代的(羧基环烷基)-烷基，—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基，X 2 和X 3 是键，—O—，—S—，Ar是二价芳香族等)，R 2 是可选地由酰氧基和/或羟基取代的烷基，R 3 是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性，用于预防或治疗高脂血症。
• Vitronectin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20010034445A1

  公开（公告）日：2001-10-25

  Compounds of formula (I) are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis. 1

  式(I)的化合物被披露，它们是在治疗骨质疏松症中有用的维特龙蛋白受体拮抗剂。
• Cytotoxins, Prodrugs, Linkers and Stabilizers useful therefor
  申请人：Medarex, Inc.

  公开号：EP2266986A1

  公开（公告）日：2010-12-29

  The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the inker arms of the invention.

  本发明提供了具有强效细胞毒性的二胭脂虫毒素类似物。本发明还提供了可在体内裂解的肽键和二硫键。这些连接体可用于形成本发明细胞毒素的原药和共轭物以及其他诊断和治疗分子。本发明提供了具有本发明嵌合臂的杜卡霉素类似物的原药和共轭物。
• VITRONECTIN RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0895475A1

  公开（公告）日：1999-02-10
• EP0895475A4
  申请人：——

  公开号：EP0895475A4

  公开（公告）日：2000-08-23